The bipolar depression market is anticipated to increase during the forecast period (2026–2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others and healthcare spending across the 7MM, reports DelveInsight.

LAS VEGAS, March 11, 2026 /PRNewswire/ -- Recently published Bipolar Depression Market Insights report includes a comprehensive understanding of current treatment practices, bipolar depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Bipolar Depression Market Summary

• The total bipolar depression treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest bipolar depression treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Bipolar depression has the highest prevalence among diagnosed cases in the US within the 18–25 age group, affecting approximately 3.40% of this population.
• Leading bipolar depression companies, such as Xenon Pharmaceuticals, Autobahn Therapeutics, AbbVie, Alto Neuroscience, NRx Pharmaceuticals, LB Pharmaceuticals, and others, are developing new bipolar depression treatment drugs that can be available in the bipolar depression market in the coming years. 
• The promising bipolar depression therapies in clinical trials include Azetukalner, Elunetirom (ABX-002), ABBV-932, ALTO-100, NRX-101, LB-102, Icalcaprant (ABBV-1354), and others.

Discover what is the CAGR for bipolar depression therapeutics market @ https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the Growth of the Bipolar Depression Market 

• Rising Bipolar Depression Prevalence: According to DelveInsight's estimates, the diagnosed prevalent cases of bipolar depression are expected to increase during the forecast period due to improved diagnostic tools, genetic predisposition research, and stress-related lifestyle changes contributing.
• Technological & Diagnostic Innovations: Advances in diagnostic tools, including imaging, biomarkers, and digital mood tracking tools, enhance early detection and personalized treatment planning.
• Launch of Emerging Drugs: The dynamics of the bipolar depression market are expected to change in the coming years owing to the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others.

Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that despite advancements, bipolar depression continues to be difficult to treat, with many patients experiencing relapse or inadequate symptom control. Emerging therapies targeting novel pathways, including dopamine and glutamate modulation, offer hope for more effective, personalized treatments.

Bipolar Depression Market Analysis

• The pharmacological treatment of bipolar depression primarily involves mood stabilizers like lithium and valproate, along with atypical antipsychotics such as quetiapine, lurasidone, and the olanzapine/fluoxetine combination. 
• The growing demand for these medications is driven by their effectiveness in managing depressive episodes and preventing relapse.
• Newer-generation antipsychotics with improved safety profiles and fewer side effects are gaining market traction.
• Approved treatments for bipolar depression include FANAPT, marketed by Vanda Pharmaceuticals, and VRAYLAR, marketed by AbbVie, among others.
• Despite available options, substantial unmet needs persist due to suboptimal response, delayed diagnosis, and poor long-term adherence.
• Current therapies present safety concerns, including metabolic and cognitive side effects.
• Innovative therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others are in development and may offer new future treatment options.

Bipolar Depression Competitive Landscape

Some of the bipolar depression drugs under development include Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others.

Xenon Pharmaceuticals' Azetukalner is an experimental oral modulator of Kv7 potassium channels being evaluated for bipolar depression. Its goal is to stabilize excessive neuronal activity and ease depressive symptoms without causing mania or the common side effects associated with antipsychotic medications.

Autobahn Therapeutics' ABX-002 is an orally administered, brain-targeted thyroid hormone beta receptor (TRβ) agonist intended to act specifically within neural regions linked to depression. It demonstrates strong therapeutic potential while limiting the peripheral adverse effects typically seen with synthetic thyroid hormones. This novel strategy may offer a safer, more effective treatment avenue for mood disorders, improving outcomes with fewer systemic risks.

AbbVie's ABBV-932 is a selective modulator of the D3 dopamine receptor that is being developed as a standalone therapy for bipolar disorder and generalized anxiety disorder. In partnership with Gedeon Richter, the program focuses on fine-tuning dopamine circuits related to mood and anxiety. By specifically targeting D3 receptors, ABBV-932 aims to deliver a more precise therapeutic option that could enhance symptom management while reducing side effects compared to current treatments.

Alto Neuroscience's ALTO-100 is a first-of-its-kind oral small molecule thought to enhance neuroplasticity within the hippocampus, an area of the brain essential for both mood regulation and cognition. It is based on the long-held theory that reduced hippocampal neuroplasticity contributes to depression and is therefore intended for patients whose cognitive patterns suggest such a deficit. ALTO-100 is currently in Phase 2b trials as an adjunctive therapy for bipolar depression.

NRx Pharmaceuticals' NRX-101 is a proprietary oral combination of two FDA-approved medications: D-cycloserine, which acts as an NMDA receptor modulator at certain doses, and lurasidone, a 5-HT2A receptor blocker. If cleared by the U.S. FDA and other regulators, it would represent the first treatment regimen specifically designed for severe bipolar depression in patients experiencing acute or sub-acute suicidal thoughts or behaviors (ASIB & SSIB).

The anticipated launch of these emerging therapies are poised to transform the bipolar depression market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the bipolar depression market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about emerging bipolar depression therapies in clinical trials @ Bipolar Depression Drugs 

Recent Developments in the Bipolar Depression Market

• In January 2026, Autobahn Therapeutics reported that topline results from the Phase II AMPLIFY-BD trial evaluating adjunctive azetukalner in bipolar depression are expected in the second quarter of 2026.
• In January 2026, JP Morgan Healthcare Conference reported that the Phase III X-CEED study evaluating azetukalner in patients with bipolar depression I or II is underway.

What is Bipolar Depression?

Bipolar depression is the depressive phase of bipolar disorder, a mood disorder characterized by extreme shifts in energy, activity, and emotions. During depressive episodes, a person may experience deep sadness, hopelessness, low motivation, sleep changes, and difficulty concentrating. Unlike ordinary depression, bipolar depression occurs as part of a cycle that also includes episodes of mania or hypomania, where mood and energy levels are unusually elevated. Understanding bipolar depression is important because its symptoms, causes, and treatment approaches can differ from other forms of depression, and effective management often requires a combination of medication, therapy, and lifestyle support.

Bipolar Depression Epidemiology Segmentation

The bipolar depression epidemiology section provides insights into the historical and current bipolar depression patient pool and forecasted trends for the leading markets. The prevalence of bipolar depression in the UK, Germany, and Italy is approximately 1%, highlighting the disorder's significant presence across different populations in Europe.

The bipolar depression treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Diagnosed Prevalent Cases of Bipolar Depression
• Type-specific Diagnosed Prevalent Cases of Bipolar Depression
• Severity-specific Diagnosed Prevalent Cases of Bipolar Depression
• Age-specific Diagnosed Prevalent Cases of Bipolar Depression

Scope of the Bipolar Depression Market Report

• Therapeutic Assessment: Bipolar Depression current marketed and emerging therapies
• Bipolar Depression Market Dynamics: Key Market Forecast Assumptions of Emerging Bipolar Depression Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Bipolar Depression Market Access and Reimbursement

Download the report to understand antipsychotics vs antidepressants in bipolar depression @ Bipolar Depression Market Analysis

Table of Contents

Related Reports

Bipolar Depression Clinical Trial Analysis

Bipolar Depression Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bipolar depression companies, including NRx Pharmaceuticals, Inc., Autobahn Therapeutics, Sunovion Pharmaceuticals Inc., and others.

Generalized Anxiety Disorder Market

Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key generalized anxiety disorder companies including VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics INC., Bionomics Limited, Receptor Life Sciences, MannKind Corporation, and others.

Schizophrenia Market

Schizophrenia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key schizophrenia companies including Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, Bristol Myers Squibb, Royalty Pharma, Acadia Pharmaceuticals, Rovi Pharmaceuticals Laboratories (Laboratorios Farmacéuticos Rovi), Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Mitsubishi Tanabe Pharma, Luye Pharma, Newron Pharmaceuticals, and others.

Social Anxiety Disorder Market

Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key social anxiety disorder companies including Mochida Pharmaceutical, Lundbeck, Vistagen Therapeutics, Bionomics, EmpowerPharm, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

info@delveinsight.com

+14699457679

www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/bipolar-depression-market-expected-to-witness-accelerated-expansion-during-the-forecast-period-20262036-amid-advancements-in-psychiatric-therapies--delveinsight-302710471.html

Zalando hat 2025 kräftig zugelegt und seine eigenen Ziele am oberen Ende der Spannen erreicht. Der Umsatz des im DAX notierten Online-Modehändlers stieg um 16,8 Prozent auf 12,35 Milliarden Euro und lag damit leicht über den Markterwartungen. Das Bruttowarenvolumen (GMV) kletterte um 14,7 Prozent auf 17,56 Milliarden Euro. Rückenwind bekam das Geschäft vor allem durch die Übernahme des Konkurrenten About You sowie den verstärkten Einsatz Künstlicher Intelligenz in Vertrieb und Plattformsteuerung.

Operativ verbesserte sich Zalando ebenfalls: Das bereinigte Ergebnis vor Zinsen und Steuern (EBIT) erhöhte sich auf 591 Millionen Euro nach 511 Millionen Euro im Vorjahr, die Marge blieb mit 4,8 Prozent stabil und leicht über den Analystenprognosen. Unter dem Strich sank der Gewinn jedoch auf 213 Millionen Euro von zuvor 251 Millionen Euro und verfehlte damit die Erwartungen. Für das laufende Jahr stellt das Management ein weiteres Wachstum von 12 bis 17 Prozent bei GMV und Umsatz in Aussicht; das bereinigte EBIT soll auf 660 bis 740 Millionen Euro steigen. Die mittelfristigen Ziele bis 2028 – jährliche Zuwächse von 8 bis 13 Prozent bei Umsatz und GMV sowie eine EBIT-Marge von 6 bis 8 Prozent – wurden bestätigt, die angepeilten jährlichen Synergien aus der About-You-Übernahme von 100 Millionen Euro sollen bereits 2028 und damit ein Jahr früher erreicht sein.

An der Börse sorgte vor allem die Kapitalmarktpolitik für Auftrieb. Der Konzern kündigte ein Aktienrückkaufprogramm von bis zu 300 Millionen Euro an, das bis Ende Juli laufen soll. Die Aktie legte im Tagesverlauf zweistellig zu und notierte zeitweise rund elf Prozent höher bei 22,35 Euro. Damit reagierte der Markt positiv auf die Kombination aus besser als erwarteten operativen Kennzahlen, bestätigtem Wachstumskurs und der Ankündigung, überschüssiges Kapital an die Anteilseigner zurückzuführen – obwohl die Zalando-Papiere seit Jahresbeginn deutlich im Minus liegen und in den vergangenen zwölf Monaten rund ein Drittel an Wert verloren haben. Analysten hoben neben dem Rückkauf insbesondere die Rolle von KI und das Konzept des sogenannten Agentic Commerce als nächste Entwicklungsstufe des Onlinehandels hervor.

Überschattet werden die guten Zahlen von strukturellen Einschnitten im Logistiknetz. Im Zuge der Integration von About You will Zalando vier Logistikzentren in Europa schließen, darunter den Standort Erfurt mit rund 2.700 Beschäftigten. Co-Chef David Schröter sprach von einer der schwersten, zugleich aber notwendigen Entscheidungen, um die Kapazitäten an den künftigen Wachstumsbedarf anzupassen. Das Unternehmen verhandelt nach eigenen Angaben mit dem Betriebsrat über einen Sozialplan, bietet Versetzungen an andere Standorte an und arbeitet mit der örtlichen Arbeitsagentur zusammen. Weitere Maßnahmen über die bereits angekündigten Schließungen hinaus soll es dem Management zufolge nicht geben; aus der Thüringer Landespolitik kommt dennoch Kritik an der Entscheidung.